Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody.
Int J Hematol
; 115(1): 7-10, 2022 Jan.
Article
in English
| MEDLINE | ID: covidwho-1604920
ABSTRACT
We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Lymphoma, B-Cell
/
Antibodies, Monoclonal, Humanized
/
COVID-19
/
BNT162 Vaccine
Topics:
Long Covid
/
Vaccines
/
Variants
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Int J Hematol
Journal subject:
Hematology
Year:
2022
Document Type:
Article
Affiliation country:
S12185-021-03247-y
Similar
MEDLINE
...
LILACS
LIS